Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically proven acute myeloid leukemia (AML) (except acute promyelocytic leukemia \[APL\] with the t(15;17) translocation) or intermediate, high-risk, or very high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R) which is relapsed or refractory (R/R) to standard therapy and/or for which standard therapy is contraindicated or which has not adequately responded to standard therapy.~* Patients must have documented IDH1-R132 gene-mutated disease as evaluated by the site~* Good performance status~* Good kidney and liver function~Exclusion Criteria:~* Patients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy~* Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias~* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PH1 Dose Escalation & Expansion FT-2102 (olutasidenib) (Type: EXPERIMENTAL): None
- PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine (Type: EXPERIMENTAL): None
- PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine (Type: EXPERIMENTAL): None
- PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent (Type: EXPERIMENTAL): Relapsed or Refractory (R/R) AML
- PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent (Type: EXPERIMENTAL): AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
- PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent (Type: EXPERIMENTAL): R/R AML/MDS, previously treated with FT-2102
- PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine (Type: EXPERIMENTAL): R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
- PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine (Type: EXPERIMENTAL): R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
- PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine (Type: EXPERIMENTAL): R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment
- PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent (Type: EXPERIMENTAL): Treatment naïve AML for whom standard treatments are contraindicated
- PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine (Type: EXPERIMENTAL): Treatment naïve AML who are candidates for azacitidine first line treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete